Analysts' Top 5 Price Targets of January 23, 2026

Revolution Medicines [US76155X1000] Stifel reaffirms Buy rating and simultaneously doubles the price target from $85 to $170 (43% upside potential) Particularly highlighted is the extraordinary rarity of so-called pan-RAS inhibitors, which are considered an extremely promising class of drugs, and whose full value, in the analysts' view, is not adequately reflected in the previous five-year forecasts. In the event of a merger or acquisition, Stifel estimates the company's value at approximately $36 billion, which corresponds to about 4.7 times...